Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

2(33%)

Results Posted

25%(1 trials)

Phase Distribution

Ph not_applicable

33%

Ph phase_1

50%

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

3(50.0%)

Phase 3Large-scale testing

1(16.7%)

N/ANon-phased studies

2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Detailed Status

Completed4

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (50.0%)

Phase 31 (16.7%)

N/A2 (33.3%)

Trials by Status

completed467%

recruiting233%

Recent Activity

2 active trials

Showing 5 of 6

completedphase_1

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117

completedphase_1

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695130

recruitingnot_applicable

Clinical Trials (6)

Showing 6 of 6 trials

NCT06695117Phase 1

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

Completed

NCT06695130Phase 1

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

Completed

NCT06150742Not Applicable

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Recruiting

NCT05401578Phase 3

Canakinumab for the Treatment of Postprandial Hypoglycemia

Recruiting

NCT03821545Not Applicable

The Anti-inflammatory Effect of Anesthetics in Abdominal Surgery

Completed

NCT01619423Phase 1

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer